An Open-Label Phase 1b Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of ANX005 in Patients with Huntington&#39;s Disease.

tanruprubart (ANX005) - Annexon Biosci

http://www.ncbi.nlm.nih.gov/pubmed/41787606

Andrew Duker; Ann Mongan; Benjamin Hoehn; Burton Scott; Daniel Claassen; Ellen Cahir-McFarland; Glenn Morrison; Henk-André Kroon; Karen Anderson; Lori Taylor; Marissa Dean; Ping Lin; Pinky Agarwal; Rajeev Kumar; Sanjay Keswani; Ted Yednock

Mar 6, 2026